NAD+ vs MOTS-c: evidence, cost, and legality

Which is better, NAD+ or MOTS-c?

NAD+ wins on evidence grade (human RCT for precursors versus animal only), on WADA status, and on access, since oral precursors are lawful supplements that need no prescription. Both injectable forms are in regulatory limbo: NAD+ is a nominated 503A bulk substance compounded under FDA's interim policy, and MOTS-c is awaiting a final FDA rule after a favorable July 2026 PCAC vote. Anyone choosing NAD+ should know the trial evidence supports oral NR and NMN, not infusions, and that a 2025 meta-analysis found no effect on muscle mass or function. [1] [2] [3] [4] [6] [9] [10] [11]

How do NAD+ and MOTS-c compare?

NAD+ and MOTS-c compared by dimension
Dimension	NAD+Favored	MOTS-c
Evidence grade [1] [2] [6] [7] [8]	Human RCT, for oral precursors: NR 1,000 mg per day raised blood NAD+ about 60% in 24 older adults; NMN 250 mg per day improved muscle insulin sensitivity about 25% in 25 prediabetic women.	Animal only. Mouse studies of obesity, insulin resistance, and running capacity; human data are exercise induced blood levels and a genetic association.
What it is [5] [6]	A coenzyme (a dinucleotide, not a peptide) used in energy metabolism and consumed by sirtuins, PARP, and CD38.	A 16 amino acid peptide encoded in the mitochondrial 12S rRNA gene.
Mechanism [3] [5] [6]	Restores cellular NAD+ that falls with age; precursors enter the salvage pathway. Intravenous NAD+ is largely broken down in blood before reaching cells.	Activates AMPK via folate cycle inhibition and AICAR accumulation, raising muscle glucose uptake and fat oxidation in mice.
Injectable form evidence [3] [6] [7]	One open label pilot: a 6 hour infusion in 11 healthy men, plasma NAD+ did not rise until the second hour and no clinical endpoints were measured.	No human study of injected MOTS-c; mice received 0.5 to 15 mg/kg.
Side effects [1] [2] [6]	Oral precursors well tolerated in trials; IV NAD+ commonly causes chest pressure, nausea, cramping, and flushing when infused quickly.	No human safety data; theoretical added glucose lowering with diabetes drugs.
FDA and compounding status [9] [10]	Not FDA approved. Nominated for the 503A bulks list and compounded under FDA's interim enforcement policy where states permit; oral NR and NMN are sold as supplements.	Not FDA approved. Removed from Category 2 on April 15, 2026; PCAC recommended it for the 503A bulks list on July 23 to 24, 2026; no final rule at verification.
WADA status [11]	Not prohibited as a substance.	Prohibited at all times under S4.4 (metabolic modulators), where it is named as an activator of AMP-activated protein kinase.
Note: Under WADA method M2, intravenous infusions or injections above 100 mL per 12 hour period are prohibited for athletes outside legitimate hospital care, which can apply to NAD+ drips.
Cost and access [9] [10]	Oral NR or NMN roughly 30 to 100 USD per month over the counter; IV sessions 300 to 1,000 USD; compounded injections roughly 150 to 400 USD per month.	No lawful compounded channel today: PCAC recommended it for the 503A bulks list in July 2026, but the recommendation is advisory and FDA has not published a final rule.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

NAD+ and MOTS-c: grade, status, and cost
Attribute	NAD+	MOTS-c
Class	Coenzyme (a dinucleotide, not a peptide) central to redox metabolism and sirtuin and PARP signaling; sold as intravenous or subcutaneous NAD+ and as oral precursors	Mitochondrial derived peptide (16 amino acids) encoded in the 12S rRNA region of mitochondrial DNA
What it is	A coenzyme, not a peptide, whose precursors raise blood NAD+ in human RCTs; clinical benefits and IV NAD+ itself remain largely unproven.	A 16 amino acid peptide coded by mitochondrial DNA that improves metabolism and exercise capacity in mice; human data limited to blood levels and genetics.
Evidence	Evidence: Human RCT evidence	Evidence: Animal-only evidence
FDA status	Regulatory: Under FDA review	Regulatory: Under FDA review
Compounding	NAD+ (nicotinamide adenine dinucleotide) is not an FDA approved drug. It was nominated for the FDA 503A bulks list and appears on the nominated substances lists pending FDA evaluation; no final rule placing it on or excluding it from the bulks list had been published as of the last verification date, so compounded NAD+ injections and infusions are dispensed under FDA's interim enforcement policy where state boards permit. Oral NR and NMN are sold as dietary supplements, and FDA has questioned whether NMN qualifies as a dietary ingredient because of prior drug investigation.	MOTS-c was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023 and removed from it on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding MOTS-c to the 503A bulks list. As of the last verification date FDA has not published a final rule, so compounding pharmacies and state boards vary in whether they will fill it. It is not an FDA approved drug and is not eligible for 503B outsourcing.
WADA	WADA: Not WADA prohibited	WADA: WADA prohibited
Routes	Oral precursors: nicotinamide riboside, nicotinamide mononucleotide (dietary supplements), Intravenous infusion of NAD+ (clinics, compounded), Subcutaneous or intramuscular NAD+ injection (compounded), Intranasal and transdermal products exist without absorption data	Subcutaneous injection (as sold), Intraperitoneal injection (animal studies)
Typical cost	IV NAD+ at a published clinic menu costs about 450 to 900 USD per session for 500 to 1,000 mg (member prices from 400 USD); compounded subcutaneous NAD+ through telehealth is about 79 to 199 USD per month. Oral NR or NMN supplements are sold over the counter. Prices checked 2026-09-22 on published provider and pharmacy price pages.	No lawful compounded price: MOTS-c is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 23, 2026	Sep 27, 2026

Has NAD+ been tested directly against MOTS-c?

No published trial has compared NAD+ and MOTS-c directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do NAD+ and MOTS-c cost?

Typical cost of NAD+ and MOTS-c
Dimension	NAD+	MOTS-c
Typical cost	$79 to $199 per month	No lawful compounded price: MOTS-c is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	NAD+ price by channel	MOTS-c price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is NAD+ or MOTS-c better for energy and aging?

Neither has shown an effect on energy, aging, or longevity in human trials. NAD+ precursors raise blood NAD+ and NMN improved muscle insulin sensitivity in one trial, but a 2025 meta-analysis found no effect on muscle mass or function. MOTS-c evidence is limited to mice. [1] [2] [4] [7]

Does IV NAD+ work better than oral precursors?

There is no evidence that it does. The only published infusion study was an 11 person pharmacokinetic pilot with no clinical endpoints, and it found that much of the infused NAD+ is broken down and excreted. The randomized trial evidence is for oral nicotinamide riboside and nicotinamide mononucleotide. [1] [2] [3]

Can athletes use either one?

MOTS-c is prohibited at all times under WADA section S4.4 (metabolic modulators). NAD+ itself is not a prohibited substance, but IV drips above 100 mL per 12 hours fall under the prohibited method M2 outside legitimate hospital care. [11]

Do I need a prescription?

Not for oral NAD+ precursors, which are dietary supplements. Injectable NAD+ requires a prescription filled by a 503A compounding pharmacy. MOTS-c is not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk. Neither is an FDA approved drug. [9] [10]

Can they be combined?

No study has tested NAD+ and MOTS-c together, so there is no evidence on the combination's benefit or safety. Both are proposed to affect glucose metabolism, so people on diabetes medications should involve their prescriber. [2] [6]

Conditions studied

From the blog

MOTS-c for weight loss: what mouse and human studies show
MOTS-c prevented diet-induced obesity in mice, but no human trial has tested it for weight loss. What the mouse data show, what human blood studies found, and where it stands legally.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 27). NAD+ vs MOTS-c: evidence, cost, and legality. https://peptideagent.ai/compare/nad-plus-vs-mots-c
HTML link: <a href="https://peptideagent.ai/compare/nad-plus-vs-mots-c">NAD+ vs MOTS-c: evidence, cost, and legality</a>, PeptideAgent, updated September 27, 2026.

NAD+ vs MOTS-c

The short answer